Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
Status:
Enrolling by invitation
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this open-label, multicenter study is to determine the long-term safety,
pharmacokinetics and effects of ALK-001 (C20-D3-retinyl acetate) on the progression of
Stargardt disease. This study is an extension of NCT02402660 and enrolls participants who are
at least 8 years old. Enrollment is by invitation only.
Funding Source - FDA OOPD